All News

Found 11,791 articles

• GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine

  7/20/2023

  LimmaTech Biologics AG signed an in-license agreement with GlaxoSmithKline Biologicals SA enabling LimmaTech Bio to further develop and commercialize a quadrivalent bioconjugate vaccine candidate for shigellosis that GSK added to its infectious disease pipeline when LimmaTech Bio’s predecessor company, GlycoVaxyn, was acquired by GSK in 2015.

• GSK is first to ship influenza vaccine doses for the 2023-24 flu season in US

  7/13/2023

  GSK plc announced it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2023-24 flu season.

• Maryland Tech Council Welcomes New Chair and Slate of Industry Leaders to its Board of Directors

  7/11/2023

  The Maryland Tech Council, the largest technology and life sciences trade association in the state, welcomed a new chair and slate of technology and life sciences leaders to its board of directors.

• InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer

  6/28/2023

  InflaRx N.V. today announced the appointment of Dr. Camilla Chong as Chief Medical Officer (CMO) of InflaRx, effective July 1, 2023.

• Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer

  6/28/2023

  Ovid Therapeutics Inc. today announced leadership appointments intended to enhance the execution of its corporate strategy and the scientific stewardship of its therapeutic development programs.

• US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes to recommend AREXVY for the prevention of RSV disease in adults aged 60 and older with shared clinical decision making

  6/22/2023

  GSK plc announced that the US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted in favor of recommending the use of AREXVY in adults aged 60 and older using shared clinical decision making.

• Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors

  6/20/2023

  Nexcella, Inc., announced that effective , Jeffrey H. Cooper, former Chief Financial Officer of BioMarin Pharmaceutical Inc., has been appointed to the Company’s Board of Directors.

• Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors

  6/20/2023

  Nexcella, Inc., a subsidiary of Immix Biopharma, Inc., announced that effective , Jeffrey H. Cooper, former Chief Financial Officer of BioMarin Pharmaceutical Inc., has been appointed to the Company’s Board of Directors.

• Adaptive Phage Therapeutics Closes on $12 Million Investment in $30 Million Series B1 to Fight Antibiotic Resistant Infections

  6/13/2023

  Adaptive Phage Therapeutics announced that it has received a $12 million upfront investment from funds managed by Deerfield Management and the AMR Action Fund as part of a new $24 million total investment in a Series B1 round that is targeting $30 million in aggregate.

• 

  FDA Action Alert: BMS, GSK, Ironwood, Ipsen/Albireo

  6/12/2023

  The FDA has four target action dates this week for three supplemental approvals and one New Drug Approval.

• Pulmocide Announces Expansion of Management Team

  6/8/2023

  Pulmocide Ltd. today announced the appointments of Matt Dallas as its Chief Financial Officer and Ashish Sagrolikar as its Chief Commercial Officer.

• Theralase(R) Announces Appointment of New Independent Director

  6/6/2023

  Theralase Technologies Inc. is pleased to announce the appointment of new independent director, Kaouthar Lbiati, M.D., M.Sc.

• ANGLE Announces Senior Management Appointments

  6/5/2023

  ANGLE plc, a world-leading liquid biopsy company, is delighted to announce the appointments of Brett Swansiger as Chief Commercial Officer and Karen Miller PhD as Chief Scientific Officer.

• GSK Announces the COiMMUNITY Initiative to Help Achieve Higher Adult Vaccination Rates in the US

  6/1/2023

  GSK plc announced the launch of the COiMMUNITY Initiative to help reduce health inequities and set a new precedent for adult immunization rates in the US, which continue to remain below pre-pandemic levelsi.

• $3.06Bn by 2027, Pharmaceutical Continuous Manufacturing Market Size, 9.8% CAGR Lead by Integrated Systems - Exclusive Research Report by The Insight Partners

  6/1/2023

  According to our new research study on “Pharmaceutical Continuous Manufacturing Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product (Integrated Systems, Semi-Continuous Systems, Controls); Application

• Almaden Genomics Names Board of Advisors

  5/31/2023

  Almaden Genomics has announced its Board of Advisors, a highly regarded group of healthcare leaders from both the public and private sectors with experience in cancer research, presicion medicine, biotechnology, clinical trials, bioinformatics, data visualization, computational analysis, pharmacology, and AI.

• Protein Binding Assay Market ($694.63 Million by 2028) Growth Forecast at 10.7% CAGR During (2021-2028) – The Insight Partners

  5/31/2023

  According to our new research study on “Protein Binding Assay Market to 2028 – Global Analysis and Forecast – by Technology, End User, and Geography,” the Protein Binding Assay Market Size is projected to reach US$ 694.63 million by 2028 from US$ 340.14 million in 2021; it is expected to grow at a CAGR of 10.7% during 2021–2028.

• Peptide Therapeutics Market (Type, Application) to Outstrip $50,003.15 Million by 2027 Growing Sturdy at 9.2% CAGR – The Insight Partners

  5/31/2023

  According to our new research study on “Peptide Therapeutics Market to 2027 – Global Analysis and Forecast – by Type, Route of administration, Synthesis Technology, and Application,” the Peptide Therapeutics Market Size was valued at US$ 24,878.55 million in 2019 and is projected to reach US$ 50,003.15 million by 2027;

• Gastrointestinal Drugs Market (Type, Application) Growth Sturdy at 4.9% CAGR to Outstrip $71,300.28 Million by 2027 – The Insight Partners

  5/31/2023

  According to our new research study on “Gastrointestinal Drugs Market to 2027 – Global Analysis and Forecast – by Drug Class, Route of Administration, Application, and Distribution Channel,” the Gastrointestinal Drugs Market Size was valued at US$ 49,043.38 million in 2019 and is projected to reach US$ 71,300.28 million by 2027;

• Virology Market (Type, Application) Valuation to Outstrip $5.27Bn by 2028 Growth Projection at 3.6% CAGR During 2021 to 2028 | The Insight Partners

  5/31/2023

  According to our latest study on “Virology Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type, Application, End User, and Geography,” the Virology Market is projected to reach US$ 5,276.48 million by 2028 from US$ 4,108.27 million in 2021;